



## Exicure to Present at Upcoming Investor Conferences

September 3, 2019

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following investor conferences during the months of September and early October:

- **H.C. Wainwright 21<sup>st</sup> Annual Global Investment Conference**

*Corporate update*

Presented by: CEO David Giljohann

Monday, September 9, 2019 at 10:25am ET

Location: New York, NY

- **Ladenburg Thalmann 2019 Healthcare Conference**

*Corporate update*

Presented by: CEO David Giljohann

Tuesday, September 24, 2019 at 1:30pm ET

Location: New York, NY

- **Chardan's 3rd Annual Genetic Medicines Conference**

*Corporate update*

Presented by: Dr. David Giljohann

Monday, October 7, 2019 at 2:00pm ET

Location: New York, NY

*The Next Big Thing in Genetic Medicines*

Panelist: Dr. David Giljohann

Tuesday, October 8, 2019 at 9:30am ET

Location: New York, NY

An audio webcast will be available on the Investors section of Exicure's website: [www.exicuretx.com](http://www.exicuretx.com). The webcast will be archived for approximately 30 days following the event.

### About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA. [www.exicuretx.com](http://www.exicuretx.com)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190903005116/en/>

Source: Exicure, Inc.

MacDougall  
Karen Sharma  
781-235-3060  
[ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)